SGLT2 inhibitors in cardiovascular disease
Update on SGLT2 inhibitors use in cardiovascular and renal disease with emphasis on heart failure and guidelines. This lecture discusses the clinical trials and mechanisms how SGLT2 inhibitors (dapaglifozin, empaglifozin, canaglifozin, sotaglifozin) improve cardiovascular and renal outcomes in patients with type 2 diabetes (T2D).
Type 2 diabetes (T2D) starts with fatty liver in morbidly obese patients and progresses to diabetic cardiomyopathy and eventually diabetic kidney disease. SGLT2 inhibitors have the ability to intercept this by inhibiting sodium glucose transporter 2 (renal) but also sodium-exchangers (NHE1 and 3) in heart and kidney.
Пікірлер: 6
THANK YOU for this great Briefing!
Outstanding presentation!
Outstanding presentation very informative
Dr. Sorescu's talk about life-style change and as a recently diagnosed HF patient my attention was drawn to glifozin when I heard discussion that lab tests showed similar results to people classified as "low mass hyper-responders" responding to a FASTING regimen. My thought on that is we might get the same result from FASTING as from these super-expensive drugs.
@LemonLimes99
7 ай бұрын
Intermittent fasting is just as good as these SL drugs. Eat in a six hour window...or even tighter
What's the stethoscope for? To chase flies?